New malaria vaccine candidate enters human trial in thailand
NCT ID NCT05380388
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a new malaria vaccine called PvRII/Matrix-M in 36 healthy Thai adults aged 20-55. Half receive the vaccine, half a placebo. After three doses, 24 volunteers will be exposed to the malaria parasite in a controlled setting to see if the vaccine reduces infection. The study focuses on safety and immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PvRII/Matrix-M malaria vaccine
- What this could lead to
- If successful, this could lead to a vaccine that protects against Plasmodium vivax malaria, a major cause of illness in tropical regions.
- What could go wrong
- This is a small early-phase trial (36 people) testing safety and immune response, not yet proven to prevent malaria in the real world. The vaccine may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA VACCINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Tropical Medicine
Bangkok, 10400, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a malaria vaccine ward off another deadly disease?
- New malaria vaccine trial aims to stop recurrent fever
- Scientists deliberately infect volunteers with malaria to advance research
- Scientists deliberately infect volunteers with malaria to study the disease
- Scientists bite back: testing malaria infection with live mosquitoes
- Sudanese health workers quizzed on malaria vaccine know-how